MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Insmed

Slēgts

SektorsVeselības aprūpe

72.05 -5.43

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

72.05

Max

76

Galvenie mērījumi

By Trading Economics

Ienākumi

-15M

-236M

Pārdošana

11M

104M

EPS

-1.32

Peļņas marža

-225.53

Darbinieki

1,271

EBITDA

-47M

-244M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+36.11% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.7B

13B

Iepriekšējā atvēršanas cena

77.48

Iepriekšējā slēgšanas cena

72.05

Ziņu noskaņojums

By Acuity

45%

55%

156 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Insmed Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. apr. 23:15 UTC

Galvenie tirgus virzītāji

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025. g. 1. apr. 23:46 UTC

Tirgus saruna

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025. g. 1. apr. 23:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 1. apr. 23:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 1. apr. 23:44 UTC

Tirgus saruna

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025. g. 1. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025. g. 1. apr. 23:11 UTC

Top Ziņas

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025. g. 1. apr. 23:02 UTC

Tirgus saruna

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025. g. 1. apr. 22:31 UTC

Top Ziņas

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025. g. 1. apr. 22:26 UTC

Tirgus saruna

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025. g. 1. apr. 21:47 UTC

Top Ziņas

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025. g. 1. apr. 21:32 UTC

Top Ziņas

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025. g. 1. apr. 21:06 UTC

Tirgus saruna

Mexican Remittances See Slow Start to the Year -- Market Talk

2025. g. 1. apr. 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2025. g. 1. apr. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 1. apr. 20:47 UTC

Top Ziņas

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025. g. 1. apr. 20:47 UTC

Top Ziņas

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025. g. 1. apr. 20:20 UTC

Top Ziņas

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025. g. 1. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Fibrebond >ETN

2025. g. 1. apr. 20:11 UTC

Tirgus saruna

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025. g. 1. apr. 20:00 UTC

Top Ziņas

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025. g. 1. apr. 19:46 UTC

Top Ziņas

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025. g. 1. apr. 19:43 UTC

Tirgus saruna

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025. g. 1. apr. 19:17 UTC

Top Ziņas

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025. g. 1. apr. 19:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025. g. 1. apr. 19:03 UTC

Tirgus saruna

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025. g. 1. apr. 19:00 UTC

Tirgus saruna

Gold Slips Ahead of Tariff Day -- Market Talk

2025. g. 1. apr. 18:54 UTC

Tirgus saruna

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Salīdzinājums

Cenas izmaiņa

Insmed Prognoze

Cenas mērķis

By TipRanks

36.11% augšup

Prognoze 12 mēnešiem

Vidējais 98 USD  36.11%

Augstākais 110 USD

Zemākais 90 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Insmed — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

14

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 78.94Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

156 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.